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Background: NaV1.5 voltage-gated sodium channels are abnormally expressed in breast tumours and their expression
level is associated with metastatic occurrence and patients’ death. In breast cancer cells, NaV1.5 activity promotes the
proteolytic degradation of the extracellular matrix and enhances cell invasiveness.
Findings: In this study, we showed that the extinction of NaV1.5 expression in human breast cancer cells almost
completely abrogated lung colonisation in immunodepressed mice (NMRI nude). Furthermore, we demonstrated that
ranolazine (50 μM) inhibited NaV1.5 currents in breast cancer cells and reduced NaV1.5-related cancer cell invasiveness
in vitro. In vivo, the injection of ranolazine (50 mg/kg/day) significantly reduced lung colonisation by NaV1.5-expressing
human breast cancer cells.
Conclusions: Taken together, our results demonstrate the importance of NaV1.5 in the metastatic colonisation of
organs by breast cancer cells and indicate that small molecules interfering with NaV activity, such as ranolazine, may
represent powerful pharmacological tools to inhibit metastatic development and improve cancer treatments.
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Breast cancer is the primary cause of death by cancer in
women worldwide and patients mostly die because of
metastases appearance and development [1] which rely
in part on the ability of cancer cells to degrade and mi-
grate through extracellular matrices (ECM). Currently,
there is no treatment for specifically inhibiting metasta-
ses development. Voltage-gated sodium channels (NaV)
are essential for action potential firing and as such are
characteristic of excitable cells [2]. However, different
NaV isoforms have been found in non-excitable epithelial
human cancer biopsies and cells, such as in breast [3,4],
lung [5-7], prostate [8], cervix [9], ovarian [10,11] and
colon cancer [12], and their function, through persistent
currents at the membrane potential, enhances degrad-
ation of ECM [5,13-15]. Notably, the NaV1.5 isoform is
abnormally expressed in breast cancer biopsies, while it* Correspondence: pierre.besson@univ-tours.fr; sebastien.roger@univ-tours.fr
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unless otherwise stated.is not in non-cancerous mammary tissues [14], and its
level of expression is associated with lymph node inva-
sion, the development of metastases and a reduced sur-
vival of patients [3,16,17]. In cancer cells, it is expressed
as a neonatal splice variant showing a 7-amino acid
substitution in the segments S3 and S4 of the domain I
(DI-S3-S4) of the protein compared to the adult variant
that shows a particular pharmacology [18] and was pro-
posed to serve as a metastatic marker [16]. NaV1.5 is
functional at the plasma membrane of highly invasive
breast cancer cells [3,16,17], and its activity maintains a
pro-invasive phenotype [15], related to “mesenchymal
migration” [19]. Indeed, while the complete mechanism
involved is not yet elucidated, NaV1.5 activity was shown
i) to control Src kinase activity, cortactin phosphoryl-
ation (Y421) and the subsequent polymerisation of actin
filaments, ii) to increase the activity of the Na+/H+ ex-
changer type 1 (NHE-1), thus enhancing the efflux of
protons and the proteolytic activity of extracellularly-
released acidic cysteine cathepsins B and S [13,20].
Altogether, these results indicated that NaV1.5 promotes. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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vasion of the surrounding ECM [15]. Molecules reducing
its activity, such as tetrodotoxin, reduce cancer cell inva-
siveness in vitro [3,14,18]. Correlatively, molecules that in-
crease its activity, such as veratridine, enhance ECM
invasion [13]. However, to the best of our knowledge, the
importance of NaV1.5 expression, and the relevance for its
pharmacological inhibition, on the metastatic organ colon-
isation by breast cancer cells have never been reported so
far. Ranolazine is an antiarrhythmic drug indicated for the
treatment of chronic angina that was approved by the
Food and Drug Administration (FDA) in 2006. While it is
proposed to have several pharmacological actions, its best
characterized one is the selective inhibition of late sodium
currents [21]. This leads to a steeper Na+ gradient which,
by increasing the activity of the Na+/Ca2+ exchanger
(NCX), reduces calcium overload, and improves ventricu-
lar relaxation in pathological conditions associated with
cardiac ischemia [22].Figure 1 Ranolazine inhibits sodium current in human breast canc
cells stably expressing null target shRNA (shCTL) were studied in voltage-clam
A, Left, representative INa-voltage traces obtained from one cell before (vehic
steady-state INa-voltage relationships obtained from cancer cells before
holding potential of −100 mV. There is as statistical difference between th
Wilcoxon test). B, Availability-voltage relationships obtained in presence (
significant leftward shift of the availability-voltage relationship in presence
shifted from −84.1 ± 1.4 mV to −90.3 ± 1.7 mV in absence and presence o
in presence (red trace) or not (vehicle, black trace) of 50 μM ranolazine. Th
in presence of ranolazine, and the 1/2-activation voltage was shifted from −
respectively. (p < 0.01, Wilcoxon test).In this study we investigated how NaV1.5 expression in
human breast cancer cells affected metastatic colonisation
of organs in immunodepressed mice, and whether its
pharmacological inhibition by ranolazine reduced cancer
cell invasiveness both in vitro and in vivo.
Highly invasive MDA-MB-231 human breast cancer
cells express mRNA for NaV1.5, NaV1.6 and NaV1.7
channels [16], but only NaV1.5 channels are functional at
the plasma membrane and are giving rise to transient in-
ward sodium currents (INa) under voltage-clamp proce-
dures [13] (see Additional file 1: Material and methods).
INa-voltage (INa-V) protocols were performed using the
whole-cell configuration of the patch clamp technique
from MDA-MB-231-Luc cells modified to stably express
a null-target small hairpin RNA (shCTL). The INa-V re-
lationship, obtained from a holding potential of −100 mV,
indicated a threshold of activation around −60 mV
and maximal current of −12.1 ± 2.2 pA/pF at a voltage
of −10 mV (Figure 1A). The acute application of ranolazineer cells. Sodium currents (INa) from MDA-MB-231 breast cancer
p mode with the whole-cell configuration of the patch clamp technique.
le) and after 50 μM ranolazine treatment (Rano). Right, mean ± s.e.m.
and after incubation with 50 μM ranolazine (n = 12 cells) from a
e two conditions for voltages ranging from −35 to +40 mV (p < 0.001,
red trace) or not (vehicle, black trace) of 50 μM ranolazine. There is a
of ranolazine (p < 0.001). The half (1/2)-inactivation voltage was
f ranolazine, respectively. C, Activation-voltage relationships obtained
ere is a significant leftward shift of the activation-voltage relationship
37.1 ± 1.0 mV to −39.2 ± 0.6 mV in absence and presence of ranolazine,
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to −8.7 ± 1.7 pA/pF (p < 0.001). This decrease in the
maximal current amplitude was associated with a signifi-
cant leftward shift of the availability-voltage relationship
(Figure 1B). The half (1/2)-inactivation voltage was shifted
from −84.1 ± 1.4 mV to −90.3 ± 1.7 mV (p < 0.001) in
absence and presence of ranolazine, respectively. The
activation-voltage relationship was significantly modified
(Figure 1C), and the 1/2-activation voltage was shifted
from −37.1 ± 1.0 mV to −39.2 ± 0.6 mV (p < 0.01). There-
fore, ranolazine reduced efficiently the activity of the neo-
natal NaV1.5 isoform expressed in human breast cancer
cells. This isoform is the only one to be functional in
breast cancer cells [13,16] and we selected a population ofFigure 2 Ranolazine inhibits the NaV1.5-mediated breast cancer cell i
qPCR in shCTL and shNaV1.5 cells (n = 10 separate experiments) and comp
23 shCTL cells and in 20 shNaV1.5 cells under a depolarization from −100 t
underneath. C, shCTL and shNaV1.5 cell growth and viability after 5 days, ex
D, Cell viability of shCTL after 5 days of growth in presence of increasing c
to the control condition without ranolazine (vehicle). E, Effect of 30 μM tet
human breast cancer cell invasiveness (Kruskal-wallis analysis followed by a
Matrigel™-composed matrix treated with 50 μM ranolazine (Rano) or not. F
circularity index was calculated using ImageJ© software (n = 138–238 c
a Matrigel™-composed matrix containing DQ-Gelatin® for 24 h in presence or
was calculated as being the number of pixels corresponding to the co-localiz
phalloidin-Alexa594) and focal spots of DQ-gelatin proteolysis (coloc) (7). Re
without ranolazine (Rano, N = 375 cells) and compared using Mann–Whitney
is indicated as: *p <0.05; **p < 0.01 and ***p < 0.001. NS stands for not statisticcells stably expressing a small hairpin RNA targeting its
expression (shNaV1.5) after lentiviral transduction. This
led to a significant 89 ± 1% decrease of NaV1.5 mRNA
expression (Figure 2A), resulting in the complete dis-
appearance of sodium currents in almost all cancer cells
(Figure 2B), with no effect on cell viability (Figure 2C).
Before assessing the effect of ranolazine in reducing
cancer cell invasiveness, we addressed a possible cyto-
toxic effect of its application. Figure 2D indicates that
ranolazine, incubated for 5 days in a range of concen-
tration from 0.1 to 100 μM had no effect on cell via-
bility. It was then used at 50 μM in the 24 h invasion
experiment with Matrigel™-coated filters (Figure 2E). In
shCTL cells, cell invasiveness was reduced by 35 ± 4% withnvasiveness in vitro. A, SCN5A mRNA expression assessed by real-time
ared with a Mann–Whitney test. B, Mean ± s.e.m. peak INa recorded in
o −5 mV (Mann–Whitney test). Representative currents are shown
pressed relative to the shCTL cell line (n = 3 independent experiments).
oncentrations of ranolazine, from 0.1 to 100 μM, and expressed relative
rodotoxin (TTX) or 50 μM ranolazine (Rano) on shCTL and shNaV1.5
Dunn’s test). F, shCTL and shNaV1.5 cells were cultured for 24 h on a
-actin cytoskeleton was stained with phalloidin-AlexaFluor594. A cell
ells analysed, Mann–Whitney test). G, shCTL cells were cultured on
not of 50 μM ranolazine. A “Matrix-Focalized-degradation activity index”
ation of F-actin condensation areas (F-actin cytoskeleton was stained with
sults are expressed relative to the control condition (CTL, N = 534 cells)
test. Representative pictures are shown on the left. Statistical significance
ally different.
Figure 3 (See legend on next page.)
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Figure 3 NaV1.5 suppression, or ranolazine treatment, inhibit metastatic lung colonisation by breast cancer cells. A, Representative
bioluminescent imaging (BLI) measurement performed in the same NMRI nude mouse per condition from week 2 to week 8 after cancer cell
injection. Mice were injected with shCTL MDA-MB-231-Luc cells (shCTL), or with shNaV1.5 MDA-MB-231-Luc cells (shNaV1.5) or with shCTL
MDA-MB-231-Luc cells and treated (5 days/week) with ranolazine (50 mg/kg) (Rano) or vehicle (shCTL, shNaV1.5). B, Evolution of mice body
weight during the experiments in the same conditions than in A. C, Mean in vivo BLI value (expressed in cpm) as a function of time recorded in
the whole body of mice coming from the three groups indicated previously (shCTL, n = 18; shNaV1.5, n = 12; Rano, n = 8) (Statistical significance
is indicated as: *p <0.05, Kruskal-Wallis analysis followed by Dunn’s test). D, Representative BLI at completion of the study (8th week after
cells injection), in whole animals and ex vivo after lung isolation. E, BLI quantification of excised lungs. Box plots indicate the first quartile,
the median, and the third quartile, squares indicate the mean (shCTL, n = 18; shNaV1.5, n = 12; Rano, n = 8) (Kruskal-Wallis analysis followed
by Dunn’s test).
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tetrodotoxin (TTX), and by 18 ± 3% with ranolazine.
In comparison to shCTL cells, shNaV1.5 cancer cells,
which do not express NaV1.5, had a reduced invasiveness
of 33 ± 10%. In shNaV1.5 cells, both TTX and ranolazine
were ineffective to further reduce cell invasiveness,
suggesting that ranolazine was specific in inhibiting
NaV1.5-related invasion. NaV1.5 expression and activity
was recently shown to control the acquisition of a
pro-invasive phenotype, by maintaining a spindle-shape
morphology and by controlling the ECM proteolysis by
MDA-MB-231 cancer cells [15]. We found that ranola-
zine increased the circularity of shCTL cells, thus de-
creasing the pro-invasive morphology, to the same
extent as the complete extinction of NaV1.5 expression
(Figure 2F). Furthermore, ranolazine reduced the focal
ECM degradative activity of shCTL cells by 58.6 ± 10.0%
(Figure 2G). This activity, which is related to the inva-
dopodial activity, was monitored as being the release of
fluorescence from DQ-gelatin at focal sites of F-actin
polymerisation as previously described [15].
Because NaV1.5 was proposed to promote metastases
development from breast tumours, we assessed the im-
portance of its expression in human breast cancer cells
for the colonisation of organs. ShCTL or shNaV1.5 cells,
both expressing the luciferase gene, were injected in
the tail vein of NMRI nude mice. A third experimental
group was set with mice injected with shCTL cells and
receiving a daily intraperitoneal injection of ranolazine
(50 mg/Kg – 5 days per week). The colonisation of mice
organs by human cancer cells was followed in vivo, every
week for a total duration of 8 weeks, by biolumines-
cent imaging (BLI) after luciferin injection (Figure 3A).
There was no statistical difference in the evolution of
animal body weights between the three groups (Figure 3B).
BLI performed in living animals indicated that shCTL
cells, which express NaV1.5, strongly colonised and de-
veloped into the chest area (which was the case for 17
out of 18 mice). In contrast, shNaV1.5 cells led to a very
weak signal (1/12 mice) or no signal at all (11/12 mice) in
the chest area. Ranolazine, which inhibited NaV1.5 cur-
rents (Figure 1), significantly reduced total BLI signalin mice injected with shCTL cells. In vitro, ranolazine
treatment did not interfere with luciferase activity in
shCTL cells (Additional file 2: Figure S1) indicating
that the BLI signal recorded was indeed strongly corre-
lated with the abundance of cancer cells in mice organs.
In this experimental group, BLI signal was recorded in 5
out of 8 mice (Figure 3C). At completion of the study,
mice were sacrificed and isolated organs (lungs, brain,
liver, bones from rachis/ribs and legs) were analysed
ex vivo. In the shCTL group, all mice showed lung col-
onisation (18/18) and a small proportion also had bio-
luminescent signal in rachis and ribs (2/18) and in leg
bones (2/18). In the shNaV1.5 group, 7 mice out of 12
had lung colonisation and one (1/12) had biolumines-
cent signal in rachis and ribs. In the ranolazine group,
although 8/8 mice presented lung colonisation, bio-
luminescence was dramatically reduced by 77 ± 8%, at a
level similar to the experimental suppression of NaV1.5
(inhibition of lung BLI by 97 ± 2%) (Figure 3D, 3E). In
the ranolazine group, mice did not show BLI signal in
other organs.
While it is now well-established that NaV channels
are anomalously expressed in several epithelial tumours
and are associated with metastasis occurrence and pa-
tient mortality [12,16,17,23], the consequence of their
expression on metastatic organ colonisation was not dem-
onstrated so far. To our knowledge, this study is the
first to clearly establish a link between NaV1.5 expres-
sion in human breast cancer cells and the colonisation
of lungs in vivo. Furthermore, this study using ranola-
zine, a drug that is clinically used, shows that the
pharmacological inhibition of NaV channels could be
effective in reducing metastastic colonisation with no
apparent toxic effect. In conclusion, this study opens a
new therapeutical concept for the management of cancer
disease. Inhibitors of NaV channels, already approved for
other clinical use such as antiarrhythmics, anticonvul-
sants [17] or anaesthetics [24], or new molecules that are
even more effective in blocking neonatal variants, could
be of high interest in the prevention and/or reduction of
metastatic spreading of cancer cells at the diagnosis of
the primary tumour.
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Additional file 2: Figure S1. MDA-MB-231-shCTL cells expressing
luciferase gene were seeded at different densities then treated for 24h
with Ranolazine (50 μM, red circles) or not (black squares).
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